Epidemiology of hormone-related venous thromboembolism

Thrombosis Research

Volumn 123, Issue SUPPL. 2, 2009, Pages

  Middeldorp, Saskia ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; CHEMICALLY INDUCED DISORDER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MIDDLE AGED; REVIEW; VENOUS THROMBOEMBOLISM;

ADULT; CONTRACEPTIVES, ORAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84873650572     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70014-3     Document Type: Article

References (48)

1. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344(20):1527 35.
2. Anonymous. Cardiovascular disease and use of oral and injectable progestagen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57(5):315 24.
3. Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000;49(6):580 90.
4. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008;(4): CD003989.
5. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: Metaanalysis. Br Med J 2001;323:131-4.
6. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet 1999; 354:2036 40.
7. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel and desogestrelcontaining low dose oral contraceptives: A cross-over study. Thromb Haemost 2000;84(1):4-8.
8. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestreland desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84(1): 15-21.
9. Meijers JCM, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000;84(1):9-14.
10. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358(9291):1427-9.
11. Seaman HE, Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: A nested cohort analysis and case control study. Hum Reprod 2003 Mar;18(3):522-6.
12. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151(5):933-8.
13. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232(2):155 60.
14. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 2007;5(4):692-9.
15. World Health Organization. Medical eligibility criteria for contraceptive use, third edition. World Health Organization: 2004. Report.
16. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation [see comments]. Lancet 1994;344(8935): 1453-7.
17. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden Should we screen oral contraceptive users and pregnant women? Br Med J 1996;313(7065):1127-30.
18. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: Implications for testing? Semin Thromb Hemost 2007;33(6):573-81.
19. Lensen RPM, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996;88(11):4205-8.
20. Simioni P, Sanson BJ, Prandoni P, et al. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81(2):198 202.
21. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128(1):15-20.
22. Middeldorp S, Meinardi JR, Koopman MMW, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135(5):322-7.
23. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004;164(17):1932-7.
24. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:c within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005;3(1):79-84.
25. Van de Poel MH, Coppens M, Middeldorp S, et al. Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Results from a retrospective family cohort study. J Thromb Haemost 2005;3(Suppl 1): P0481. Abstract.
26. Coppens M, van der Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006;108:2604-7.
27. Lijfering W, Coppens M, van der Poel MH, et al. The risk of venous and arterial thrombosis in hyperhomocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007;98:457 63.
28. Bank I, Van de Poel MH, Coppens M, et al. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c: A prospective family cohort study. Thromb Haemost 2007;98:1040-4.
29. Makelburg ABU, Lijfering W, Middeldorp S, et al. Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia a prospective family cohort study in asymptomatic subjects. Thromb Haemost, in press.
30. Martinelli I. Pros and cons of thrombophilia testing: Pros. J Thromb Haemost 2003;1(3):410 1.
31. Machin SJ. Pros and cons of thrombophilia testing: Cons. J Thromb Haemost 2003;1(3):412 3.
32. Aznar J, Mira Y, Vaya A, Ferrando F, Villa P. Is family history sufficient to identify women with risk of venous thromboembolism before commencing the contraceptive pill? Clin Appl Thromb Hemost 2002;8(2):139 41.
33. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med, in press.
34. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J 1974;1:215-7.
35. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005;293(19):2352-61.
36. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database 2000; CD001367.
37. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):844S 886S.
38. Hulley S., Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280(7):605 13.
39. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study followup (HERS II). J Am Med Assoc 2002;288(1):49-57.
40. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principle results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288(3):321-33.
41. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348(9033):977 80.
42. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. Br Med J 1997;315(7101): 149 53.
43. Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT) risks and benefits. Int J Epidemiol 2001; 30(3):423-6.
44. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
45. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166(7):772 80.
46. Canonico M, Plu-Bureau, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and metaanalysis. Br Med J 2008;336(7655):1227-31.
47. Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2004;3(5):943-8.
48. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359(7):697 708.